3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Hepatocellular
46
Colorectal Neoplasms
33
Stomach Neoplasms
31
Esophageal Squamous Cell Carcinoma
27
Esophageal Neoplasms
14
Rectal Neoplasms
12
Cholangiocarcinoma
11
Colonic Neoplasms
9
Pancreatic Neoplasms
7
Neoplasm Metastasis
6
Sarcoma
5
Carcinoma, Non-Small-Cell Lung
5
Locally Advanced Rectal Cancer
4
Biliary Tract Neoplasms
4
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Melanoma
3
Liver Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma
3
Adenocarcinoma Of Esophagus
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Mesothelioma
2
Lung Neoplasms
2
HER2-positive Gastric Cancer
2
Endometrial Neoplasms
2
Digestive System Neoplasms
2
Interventions
Gemcitabine
4
lenvatinib
3
durvalumab
3
Cisplatin
3
tislelizumab
2
sintilimab
2
pembrolizumab
2
toripalimab
1
titanium silicide
1
theasinensin A
1
surufatinib
1
sitravatinib
1
regorafenib
1
S 1 (combination)
1
Nivolumab
1
Injections
1
Folfox protocol
1
Fluorouracil
1
Cryosurgery
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Advanced Biliary Tract Cancer
×
tislelizumab
×
Gastrointestinal
×
Clear all
NCT04727996
2024-04-19
BTC-BGB
Seoul National University Hospital
Phase 2
Unknown
43 enrolled
NCT05823987
2023-06-27
OPTIONS-05
Fudan University
Phase 2
Unknown
25 enrolled